Insulin and GLP-1 Agonist Combination for Variable Dosing

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diabetes treatments involving insulin and GLP-1 agonists require multiple injections and have limitations in adjusting the ratio of insulin to GLP-1, leading to potential underdosing or overdosing of either component.

Innovation Solution

A medicament comprising a combination of insulin and GLP-1 agonist, formulated to allow for variable proportions of each component, enabling administration in a single dose adapted to individual patient needs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If insulin and GLP-1 agonist are administered as separate injections, then each component can be dosed independently, but the treatment complexity increases and patient compliance decreases

Engineering Contradiction:

Improvedosing precisionVSAvoidtreatment complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent combines insulin and GLP-1 agonist into a single pharmaceutical composition that can be administered via one injection. This merging of two separate treatments into one unified formulation reduces treatment complexity and improves patient compliance while maintaining the ability to dose each component independently through separate compartments or mixing mechanisms

Inventive Principle:

Principle #5Merging (Combining)

2Ease of manufacture

If insulin and GLP-1 agonist are mixed in fixed proportions, then the formulation is simplified, but the ability to adapt to individual patient requirements is reduced

Engineering Contradiction:

Improveformulation simplicityVSAvoiddose adaptability

Core Design Contradiction:

Ease of manufactureVSAdaptability or versatility

Solution Approach 1:

The patent employs a dynamic dosing system where the ratio of insulin to GLP-1 agonist can be adjusted based on individual patient needs. This is achieved through mechanisms such as separate compartments with adjustable mixing ratios, or variable concentration formulations that allow customization of the final dose while maintaining a simplified single-injection approach

Inventive Principle:

Principle #15Dynamics

3Reliability

If multiple injections are administered throughout the day, then blood glucose control is improved, but the loss of time and patient burden increase

Engineering Contradiction:

Improveblood glucose controlVSAvoidadministration time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent provides a single injection formulation that delivers both insulin and GLP-1 agonist with sustained release characteristics, maintaining continuous blood glucose control throughout the day. This eliminates the need for multiple separate injections while ensuring reliable glycemic control through the prolonged action of both components

Inventive Principle:

Principle #20Continuity of useful action

Data Source

PatentUS20250161416A1Combination of an insulin and a GLP-1-agonist

Publication Date: 2025.05.22 SANOFI AVENTIS DEUT GMBH

AI summary

The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.